Projects per year
Personal profile
Research interests
Miller Lab Consortium. To date, our team has treated more than 400 patients with natural killer cell infusions and over a hundred patients with therapies that activate their own natural killer cells. We've retrospectively analyzed more than 5000 patients and enrolled more than 500 patients in prospective trials.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
BMT Core - University of Minnesota
Juckett, M. B. (PI), Ebens, C. (Co-Principal Investigator), Merino, A. M. (Other Role) & Miller, J. S. (Other Role)
NIH NAT'L HEART, LUNG, AND BLOOD INSTITU
8/15/24 → 6/30/31
Project: Research project
-
Evaluation of Novel TriKE-PACC Molecule to Amplify Natural Killer Cell Function in Mesothelioma
Felices, M. (PI) & Miller, J. S. (CoI)
7/15/24 → 7/14/26
Project: Research project
-
Leveraging Targeted Biological Complexes to Maximize Natural Killer Cell Immunotherapy in Lung Cancer
Felices, M. (PI), Fujioka, N. (CoI) & Miller, J. S. (CoI)
7/1/24 → 6/30/27
Project: Research project
-
Trapping Inhibitory Signals in Synergy with Cytokine Signaling to Maximize NK Cell Immunotherapy in Ovarian Cancer
Felices, M. (PI) & Miller, J. S. (CoI)
7/1/24 → 6/30/28
Project: Research project
-
Cancer Center Support Grant
Yee, D. (PI), Antonarakis, E. (CoI), Beckman, K. B. (CoI), Betts, B. (CoI), Blaes, A. H. (CoI), Eaton, A. (CoI), Ellis, K. M. (CoI), Felices, M. (CoI), Geller, M. A. (CoI), Ghebre, R. G. (CoI), Griffin, T. J. (CoI), Hallstrom, T. C. (CoI), Harki, D. A. (CoI), Hatsukami, D. K. (CoI), Hirsch, B. A. (CoI), Huang, R. S. S. (CoI), Johnson, S. (CoI), Juckett, M. B. (CoI), Lange, C. A. (CoI), Le, C. T. (CoI), Luo, X. (CoI), McKenna, D. H. (CoI), Miller, J. S. (CoI), Moriarity, B. S. (CoI), Muretta, J. M. (CoI), Murray, T. (CoI), Nelson, H. H. (CoI), Ondrey, F. G. (CoI), Patel, M. R. (CoI), Pennell, C. A. (CoI), Petersen, A. J. (CoI), Peterson, L. A. (CoI), Poynter, J. (CoI), Pratt, R. J. (CoI), Sarver, A. L. (CoI), Schendzielos, D. L. (CoI), Schilz, A. (CoI), Schwertfeger, K. (CoI), Seelig, D. (CoI), Shimizu, Y. (CoI), Stepanov, I. (CoI), Temiz, N. A. (CoI), Ventz, S. (CoI), Villalta, P. W. (CoI), Vogel, R. (CoI), Wagner, J. E. (CoI), Wang, J. (CoI), Webber, B. R. (CoI), Weigel, B. J. (CoI), Yamamoto, M. (CoI) & Zhang, L. (CoI)
NIH NATIONAL CANCER INSTITUTE (NCI)
2/1/24 → 1/31/29
Project: Research project
-
A critical threshold of MCM10 is required to maintain genome stability during differentiation of induced pluripotent stem cells into natural killer cells
Schmit, M. M., Baxley, R. M., Wang, L., Hinderlie, P., Kaufman, M., Simon, E., Raju, A., Miller, J. S. & Bielinsky, A. K., Jan 24 2024, In: Open biology. 14, 1, 230407.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant
Nakamura, R., La Rosa, C., Yang, D., Hill, J. A., Rashidi, A., Choe, H., Zhou, Q., Lingaraju, C. R., Kaltcheva, T., Longmate, J., Drake, J., Slape, C., Duarte, L., Al Malki, M. M., Pullarkat, V. A., Aribi, A., Devine, S., Verneris, M. R., Miller, J. S. & Forman, S. J. & 2 others, , 2024, In: Haematologica.Research output: Contribution to journal › Article › peer-review
Open Access -
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells
Matson, A. W., Hullsiek, R., Dixon, K. J., Wang, S., Lindstedt, A. J., Friess, R. R., Phung, S. K., Freedman, T. S., Felices, M., Truckenbrod, E. N., Wu, J., Miller, J. S. & Walcheck, B., Jul 24 2024, In: Journal for ImmunoTherapy of Cancer. 12, 7, e008959.Research output: Contribution to journal › Article › peer-review
Open Access -
High-dimensional single-cell analysis of human natural killer cell heterogeneity
Rebuffet, L., Melsen, J. E., Escalière, B., Basurto-Lozada, D., Bhandoola, A., Björkström, N. K., Bryceson, Y. T., Castriconi, R., Cichocki, F., Colonna, M., Davis, D. M., Diefenbach, A., Ding, Y., Haniffa, M., Horowitz, A., Lanier, L. L., Malmberg, K. J., Miller, J. S., Moretta, L. & Narni-Mancinelli, E. & 7 others, , Aug 2024, In: Nature immunology. 25, 8, p. 1474-1488 15 p.Research output: Contribution to journal › Article › peer-review
Open Access27 Scopus citations -
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma
Dixon, K., Snyder, K. M., Khaw, M., Hullsiek, R. H., Davis, Z. B., Matson, A. W., Shirinbak, S., Hancock, B., Bjordahl, R., Hosking, M., Miller, J. S., Valamehr, B., Wu, J. & Walcheck, B., 2024, In: Frontiers in immunology. 15, 1407567.Research output: Contribution to journal › Article › peer-review
Open Access
Press/Media
-
University of Minnesota turns natural killer cells against COVID-19
8/6/20
1 item of Media coverage
Press/Media: Expert Comment or Interview